Drug for preventing and/or treating polycystic kidney disease
An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
1. A combination for suppressing progression of polycystic kidney disease and/or treating polycystic kidney disease, wherein said combination comprises a synergistically effective amount of a sustained-release formulation of tolvaptan or a prodrug thereof, and a sustained-release formulation of vapreotide or a salt thereof.
2. The combination according to claim 1 , wherein the combination is in the form of separate formulations, and is a combination of an oral preparation comprising the sustained-release formulation of tolvaptan or a prodrug thereof, and an injectable preparation comprising the sustained-release formulation of vapreotide or a salt thereof.
3. A kit for suppressing disease progression of polycystic kidney disease and/or treating polycystic kidney disease, wherein said kit comprises a synergistically effective amount of an oral sustained-release formulation of tolvaptan or a prodrug thereof, and an injectable sustained-release formulation of vapreotide or a salt thereof.